Which anti-infective drug is preferred for the treatment of Mycoplasma pneumoniae pneumonia

Azithromycin is the first choice for the treatment of Mycoplasma pneumoniae pneumonia.

Azithromycin belongs to the macrolide class of antibiotics, which is mainly suitable for gram-positive bacteria, mycoplasma, chlamydia infection, etc., and is the preferred drug for the treatment of mycoplasma and chlamydia. Because macrolide antibiotics have a good effect on the treatment of mycoplasma and chlamydia infections and have relatively few side effects, they are the preferred type of antibiotics, and azithromycin is a new type of drug among macrolide antibiotics. Compared with the first- and second-generation macrolides, it is more effective and has fewer side effects, so it is the drug of choice for the treatment of Mycoplasma pneumoniae pneumonia.

Antibacterial and anti-inflammatory drugs that are better for Mycoplasma pneumoniae pneumoniae, as well as tetracycline drugs. However, these drugs are relatively large in terms of side effects, and are not currently (February 2022) the preferred treatment for Mycoplasma pneumoniae pneumoniae, but patients who are not susceptible to macrolide antibiotics, have drug resistance, or cannot be used for other reasons, can be treated with tetracyclines.

The main clinical symptoms of Mycoplasma pneumoniae pneumonia are fever, irritating cough, and sometimes dry cough without sputum. Mycoplasma antibody testing can confirm the diagnosis, and azithromycin can be used for treatment after the diagnosis is confirmed. In addition, other drugs of macrolides, such as roxithromycin and erythromycin, also have certain effects.